High density lipoprotein subfractions and paraoxonase 1 in children

• Authors: Jana Muchová , Lucia Andrezálová , Stanislav Oravec , Zuzana Nagyová , Iveta Garaiova , Zdeňka Ďuračková
• Languages of publication: EN

Abstracts

EN

The Lipoprint system (Quantimetrix Corp., CA, USA), enables the determination of 10 high density lipoprotein (HDL) subfractions in contrast to the 5 HDL subfractions that can be determined by ultracentrifuge analysis. HDL subfractions, and their relationships to the arylesterase (PON1-A) and lactonase (PON1-L) activities of paraoxonase 1 (PON1), together with total-, very low density lipoprotein- and low density lipoprotein (LDL)-cholesterol and LDL subfractions were investigated in the serum of 27 mildly hypercholesterolemic children and 21 healthy controls. Our results suggest the antiatherogenity of large HDL (L-HDL) subfractions and the atherogenity of small HDL (S-HDL) subfractions in the study groups. However, the relationship between the intermediate HDL (I-HDL) subfractions with the LDL subfractions and other lipoproteins did not suggest that I-HDL subfractions are antiatherogenic. No significant association between PON1-A and the HDL subfractions was found. In contrast, PON1-L activity positively correlated with the antiatherogenic large HDL1 subfraction and negatively with intermediate HDL subfractions 4, 5 and 6. Our results contribute to the knowledge of the roles of total HDL and ten individual HDL subfractions in children and adolescents.

Keywords

EN

lipoproteins; LDL-lipoproteins; HDL-lipoproteins; children; paraoxonase 1

• Publisher: Polish Biochemical Society
• Journal: Acta Biochimica Polonica
• Year: 2016
• Volume: 63
• Issue: 3
• Pages: 555-563

Dates

published

2016

received

2015-12-08

revised

2016-02-18

accepted

2016-02-25

(unknown)

2016-06-06

Contributors

author

Jana Muchová

• Institute of Medical Chemistry, Biochemistry and Clinical Biochemistry, Faculty of Medicine, Comenius University, Bratislava, Slovakia

author

Lucia Andrezálová

• Institute of Medical Chemistry, Biochemistry and Clinical Biochemistry, Faculty of Medicine, Comenius University, Bratislava, Slovakia

author

Stanislav Oravec

• 2nd Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia

author

Zuzana Nagyová

• Juvenalia Paediatric Centre, Dunajská Streda, Slovakia

author

Iveta Garaiova

• Research Department, Cultech Ltd, Unit, Port Talbot SA12 7BZ, UK

author

Zdeňka Ďuračková

• Institute of Medical Chemistry, Biochemistry and Clinical Biochemistry, Faculty of Medicine, Comenius University, Bratislava, Slovakia

References

• Ahmed Z, Ravandi A, Maguire GF, Emili A, Draganov D, La Du BN, Kuksis A, Connelly PW (2001) Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipoprotein oxidation with a peroxynitrite donor. J Biol Chem 276: 24473-24481. doi: 10.1074/jbc.M010459200.
• Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC, Schaefer EJ (2004) High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 24: 2181-2187. doi: 10.1161/01.ATV.0000146325.93749.a8.
• Aviram M, Rosenblat M (2008) Paraoxonases (PON1, PON2, PON3) analyses in vitro and in vivo in relation to cardiovascular diseases. Methods Mol Biol 477: 259-276. doi: 10.1007/978-1-60327-517-0-20.
• Benson M, Hossain J, Caulfield MP, Damaso L, Gidding S, Mauras N (2012) Lipoprotein subfractions by ion mobility in lean and obese children. J Pediatr 161: 997-1003. doi: 10.1016/j.jpeds.2012.05.060.
• Chapman MJ, Goldstein S, Lagrange D, Laplaud PM (1981) A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J Lipid Res 22: 339-358.
• D'Adamo E, Northrup V, Weiss R, Santoro N, Pierpont B, Savoye M, O'Malley G, Caprio S (2010) Ethnic differences in lipoprotein subclasses in obese adolescents: importance of liver and intraabdominal fat accretion. Am J Clin Nutr 92: 500-508. doi: 10.3945/ajcn.2010.29270.
• Daniels SR, Gidding SS, de Ferranti SD (2011) Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 5: S30-S37. doi: 10.1016/j.jacl.2011.03.453.
• Després JP (2007) Cardiovascular disease under the influence of excess visceral fat. Crit Pathw Cardiol 6: 51-59. doi: 10.1097/HPC.0b013e318057d4c9.
• Domagała TB, Łacinski M, Trzeciak WH, Mackness B, Mackness MI, Jakubowski H (2006) The correlation of homocysteine-thiolactonase activity of the paraoxonase (PON1) protein with coronary heart disease status. Cell Mol Biol 52: 4-10. doi: 10.1170/T727.
• Don MM, Masters CJ, Winzor D J (1975) Further evidence for the concept of bovine plasma arylesterase as a lipoprotein. Biochem J 151: 625-630. doi: 10.1042/bj1510625.
• Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN (2005) Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 46: 1239-1247. doi: 10.1194/jlr.M400511-JLR200.
• Fuhrman B, Partoush A, Aviram M (2004) Acetylcholine esterase protects LDL against oxidation. Biochem Biophys Res Commun 322: 974-978. doi: 10.1016/j.bbrc.2004.08.019.
• Gaidukov L, Tawfik DS (2007) The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity. J Lipid Res 48: 1637-1646. doi: 10.1194/jlr.D600045-JLR200.
• Gan KN, Smolen A, Eckerson HW, La Du BN (1991) Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 19: 100-106.
• Garaiova I, Muchová J, Nagyová Z, Mišľanová C, Oravec S, Dukát A, Wang D, Plummer SF, Ďuračková Z (2013) Effect of a plant sterol, fish oil and B vitamin combination on cardiovascular risk factors in hypercholesterolemic children and adolescents: a pilot study. Nutr J 12: 7. doi: 10.1186/1475-2891-12-7.
• Gugliucci A, Caccavello R, Kotani K, Sakane N, Kimura S (2013) Enzymatic assessment of paraoxonase 1 activity on HDL subclasses: a practical zymogram method to assess HDL function. Clin Chim Acta 415: 162-168. doi: 10.1016/j.cca.2012.10.044.
• Harangi M, Mirdamadi HZ, Seres I, Sztanek F, Molnár M, Kassai A, Derdák Z, Illyés L, Paragh G (2009) Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity. Transl Res 153: 190-198. doi: 10.1016/j.trsl.2009.01.007.
• Hoefner DM, Hodel SD, O'Brien JF, Branum EL, Sun D, Meissner I, McConnell JP (2001) Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem 47: 266-274.
• Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE (1993) The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3: 73-76. doi: 10.1038/ng0193-73.
• Jakubowski H (2000) Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem 275: 3957-3962. doi: 10.1074/jbc.275.6.3957.
• Jakubowski H (2011) Quality control in tRNA charging - Editing of homocysteine. Acta Biochim Pol 58: 149-163.
• Jakubowski H (2013) Homocysteine in Protein Structure/Function and Human Disease. Chemical Biology of Homocysteine-containing Proteins. Springer. ISBN 978-3-7091-1409-4. doi: 10.1007/978-3-7091-1410-0.
• Jakubowski H, Borowczyk K, Glowacki R, Nygård O (2015) Urinary homocysteine thiolactone predicts acute myocardial infarction in a randomized controlled homocysteine-lowering B-vitamin Trial. Circulation 132: A19250.
• James RW, Deakin SP (2004) The importance of high-density lipoproteins for paraoxonase-1 secretion, stability and activity. Free Radic Biol Med 37: 1986-1994. doi: 10.1016/j.freeradbiomed.2004.08.012.
• Jehlička P, Stožický F, Mayer O Jr, Varvařovská J, Racek J, Trefil L, Siala K (2009) Asymmetric dimethylarginine and the effect of folate substitution in children with familial hypercholesterolemia and diabetes mellitus type 1. Physiol Res 58: 179-184.
• Kaitosaari T, Simell O, Viikari J, Raitakari O, Siltala M, Hakanen M, Leino A, Jokinen E, Rönnemaa T (2009) Tracking and determinants of LDL particle size in healthy children from 7 to 11 years of age: the STRIP Study. Eur J Pediatr 168: 531-539. doi: 10.1007/s00431-008-0780-4.
• Kennedy DJ, Tang WH, Fan Y, Wu Y, Mann S, Pepoy M, Hazen SL (2013) Diminished antioxidant activity of high-density lipoprotein-associated proteins in chronic kidney disease. J Am Heart Assoc 2: e000104. doi: 10.1161/JAHA.112.000104.
• Khersonsky O, Tawfik DS (2005) Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 44: 6371-6382.
• Kontush A, Chantepie S, Chapman MJ (2003) Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 23: 1881-1888. doi: 10.1161/01.ATV.0000091338.93223.E8.
• Kwiterovich PO, Virgil DG, Chu AY, Khouzami VA, Alaupovic P, Otvos JD (2013) Interrelationships between the concentration and size of the largest high-density lipoprotein subfraction and apolipoprotein C-I in infants at birth and follow-up at 2-3 months of age and their parents. J Clin Lipidol 7: 29-37. doi: 10.1016/j.jacl.2012.09.002.
• Lacinski M, Skorupski W, Cieslinski A, Sokolowska J, Trzeciak WH, Jakubowski H (2004) Determinants of homocysteine-thiolactonase activity of the paraoxonase-1 (PON1) protein in humans. Cell Mol Biol (Noisy-le-grand) 50: 885-893.
• Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Després JP (1997) Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation 95: 69-75. doi: 10.1161/01.CIR.95.1.69.
• Macharia M, Hassan MS, Blackhurst D, Erasmus RT, Matsha TE (2012) The growing importance of PON1 in cardiovascular health: a review. J Cardiovasc Med (Hagerstown) 13: 443-453. doi: 10.2459/JCM.0b013e328354e3ac.
• Mascarenhas-Melo F, Sereno J, Teixeira-Lemos E, Marado D, Palavra F, Pinto R, Rocha-Pereira P, Teixeira F, Reis F (2013) Implication of low HDL-c levels in patients with average LDL-c levels: a focus on oxidized LDL, large HDL subpopulation, and adiponectin. Mediators Inflamm 2013: 612038. doi: 10.1155/2013/612038.
• McEneny J, Blair S, Woodside JV, Murray L, Boreham C, Young IS (2013) High-density lipoprotein subfractions display proatherogenic properties in overweight and obese children. Pediatr Res 74: 279-283. doi: 10.1038/pr.2013.93.
• McNeal CJ, Dajani T, Wilson D, Cassidy-Bushrow AE, Dickerson JB, Ory M (2010) Hypercholesterolemia in youth: opportunities and obstacles to prevent premature atherosclerotic cardiovascular disease. Curr Atheroscler Rep 12: 20-28. doi: 10.1007/s11883-009-0072-0.
• Morais J (2005) Quantimetrix shows that all HDL subfractions may not protect against heart disease. In: Quantimetrix, June 24. http://quantimetrix.com/quantimetrix-shows-that-all-hdl-subfractions-may-not-protect-against-heart-disease/.
• Muniz N, Morais J (2005) Coronary heart disease. High density lipoprotein subclasses associated with heart disease. Medical Letter on the CDL and FDA, July 31st.
• Neyer G, Muniz N, Morais J (2003) Measurement and distribution of HDL subclasses with the new Lipoprint® HDL method. Clin Chem 49: A168.
• Nobécourt E, Jacqueminet S, Hansel B, Chantepie S, Grimaldi A, Chapman MJ, Kontush A (2005) Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia 48: 529-538. doi: 10.1007/s00125-004-1655-5.
• Oravec S, Dukát A, Gavorník P, Lovásová Z, Gruber K (2011) Atherogenic normolipidemia - a new phenomenon in the lipoprotein profile of clinically healthy subjects. Neuro Endocrinol Lett 32: 317-321.
• Oravec S, Dostal E, Dukát A, Gavorník P, Kucera M, Gruber K (2011a) HDL subfractions analysis: A new laboratory diagnostic assay for patients with cardiovascular diseases and dyslipoproteinemia. Neuro Endocrinol Lett 32: 502-509.
• Oravec S, Gruber K, Dostal E, Mikl J (2011b) Hyper-betalipoproteinemia LDL 1,2: a newly identified nonatherogenic hypercholesterolemia in a group of hypercholesterolemic subjects. Neuro Endocrinol Lett 32: 322-327.
• Perla-Kaján J, Jakubowski H (2010) Paraoxonase 1 protects against protein N-homocysteinylation in humans. FASEB J 24: 931-936. doi: 10.1096/fj.09-144410.
• Perła-Kaján J, Jakubowski H (2012) Paraoxonase 1 and homocysteine metabolism. Amino Acids 43: 1405-1417. doi: 10.1007/s00726-012-1321-z.
• Pietiläinen KH, Söderlund S, Rissanen A, Nakanishi S, Jauhiainen M, Taskinen MR, Kaprio J (2009) HDL subspecies in young adult twins: heritability and impact of overweight. Obesity (Silver Spring) 17: 1208-1214. doi: 10.1038/oby.2008.675.
• Pirillo A, Norata GD, Catapano AL (2013) High-density lipoprotein subfractions - What the clinicians need to know. Cardiology 124: 116-125. doi: 10.1159/000346463.
• Racek J, Rusňáková H, Trefil L, Siala KK (2005) The influence of folate and antioxidants on homocysteine levels and oxidative stress in patients with hyperlipidemia and hyperhomocysteinemia. Physiol Res 54: 87-95.
• Rajman I, Kendall MJ, Cramb R, Holder RL, Salih M, Gammage MD (1996) Investigation of low density lipoprotein subfractions as a coronary risk factor in normotriglyceridaemic men. Atherosclerosis 125: 231-242. doi: 10.1016/0021-9150(96)05881-9.
• Rosenson RS, Brewer HB Jr, Chapman MJ, Fazio S, Hussain MM, Kontush A, Krauss RM, Otvos JD, Remaley AT, Schaefer EJ (2011) HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 57: 392-410. doi: 10.1373/clinchem.2010.155333.
• Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394: 284-287.
• Šoltésová M, Hrebík M (2006) Atherosclerosis in childhood and primary prevention (in Slovak). Pediatria (Bratisl) 1: 227-231.
• Sumegová K, Nagyová Z, Waczulíková I, Žitňanová I, Ďuračková Z (2007) Activity of Paraoxonase 1 and lipid profile in healthy children. Physiol Res 56: 351-357.
• Superko HR, Pendyala L, Williams PT, Momary KM, King SB 3rd, Garrett BC (2012) High-density lipoprotein subclasses and their relationship to cardiovascular disease. J Clin Lipidol 6: 496-523. doi: 10.1016/j.jacl.2012.03.001.
• Teiber JF, Draganov DI, La Du BN (2004) Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH. J Lipid Res 45: 2260-2268. doi: 10.1194/jlr.M400213-JLR20.
• Vekic J, Kotur-Stevuljevic J, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Topic A, Zeljkovic A, Stefanovic A, Zunic G (2007) Association of oxidative stress and PON1 with LDL and HDL particle size in middle-aged subjects. Eur J Clin Invest 37: 715-723. doi: 10.1111/j.1365-2362.2007.01849.x.

Identifiers

DOI

10.18388/abp.2015_1230